These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 23181576)

  • 1. Inhibitors of the immunoproteasome: current status and future directions.
    Miller Z; Ao L; Kim KB; Lee W
    Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunoproteasome as a therapeutic target for hematological malignancies.
    Miller Z; Lee W; Kim KB
    Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
    Kuhn DJ; Orlowski RZ; Bjorklund CC
    Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunoproteasome as a target in hematologic malignancies.
    Kuhn DJ; Orlowski RZ
    Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
    Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
    Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
    Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
    Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.
    Wang J; Fang Y; Fan RA; Kirk CJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonselective proteasome inhibitors in multiple myeloma and future perspectives.
    Gavriatopoulou M; Malandrakis P; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Opin Pharmacother; 2022 Feb; 23(3):335-347. PubMed ID: 34761710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer.
    Tripathi SC; Vedpathak D; Ostrin EJ
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunoproteasome: an emerging therapeutic target.
    Lee W; Kim KB
    Curr Top Med Chem; 2011 Dec; 11(23):2923-30. PubMed ID: 21824107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
    Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
    Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunoproteasome: a novel drug target for autoimmune diseases.
    Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoproteasome acted as immunotherapy 'coffee companion' in advanced carcinoma therapy.
    Shi S; Ou X; Liu C; Wen H; Jiang K
    Front Immunol; 2024; 15():1464267. PubMed ID: 39281672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the role of the immunoproteasome in transplant rejection.
    Basler M; Li J; Groettrup M
    Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
    Park J; Cho J; Song EJ
    Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
    Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
    Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
    Kasam V; Lee NR; Kim KB; Zhan CG
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3614-7. PubMed ID: 24913713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
    Besse L; Besse A; Kraus M; Maurits E; Overkleeft HS; Bornhauser B; Bourquin JP; Driessen C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.